Back to the top

New Coalition of Leading Cancer Research Organizations Launched to Accelerate Early Detection of Deadly Cancers

New Coalition of Leading Cancer Research Organizations Launched to Accelerate Early Detection of Deadly Cancers $12 million awarded to six collaborative teams developing new approaches to the earlier detection and diagnosis of pancreatic, ovarian, and esophageal cancers News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org New York, NY, February 3, 2026 — The Mark Foundation for Cancer Research today announced the launch of a coalition of leading nonprofit organizations dedicated to solving the critical problem of early detection and diagnosis for some of the world’s deadliest cancers. In partnership with the American Association for Cancer Research (AACR), Lustgarten Foundation,......

Continue reading

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells A multi-site trial pairs targeted therapy with next-generation MRD testing to track residual disease and uncover vulnerabilities in leukemia cells News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) December 11, 2025 – Acute myeloid leukemia (AML) is an aggressive blood cancer, with overall survival remaining approximately 30% at five years despite advances in therapy. Even when patients achieve remission, the disease often returns, fueled by a small number of leukemia cells that survive initial treatment, known as measurable residual disease (MRD). These remaining......

Continue reading

More Than a Patient: How Holly Folgia Turned Her Cancer Journey Into Impact

More Than a Patient: How Holly Folgia Turned Her Cancer Journey Into Impact Holly's journey with stage IV ovarian cancer is one of resilience, creativity, and generosity. As a participant in a Break Through Cancer-funded clinical trial at Memorial Sloan Cancer Center, she is a part of the Targeting Minimal Residual Disease in Ovarian Cancer TeamLab's work to bring new treatment options to patients facing one of the deadliest cancers for women. While undergoing treatment, Holly published a children's book, I Hope You Know, a heartfelt story about the bond between mother and child. She is donating half of the proceeds to ovarian and......

Continue reading

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say | The ASCO Post

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say November 20, 2025 Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery could stop many ovarian cancers from ever developing. Read More at The ASCO Post....

Continue reading

Conquering Cancer: Innovations Closing Gaps and Improving Outcomes | Milken Institute

Jesse Boehm at the Future of Health Summit 2025: Conquering Cancer Panel We are pleased to share that our Chief Scientific Officer, Jesse Boehm, participated as a speaker at the 2025 Future of Health Summit, hosted by the Milken Institute in Washington, DC. The Summit brought together more than 200 experts and 1,400 participants to discuss biomedical innovation, equitable access, chronic disease prevention, and the future of global health. As part of the program, Jesse joined the panel “Conquering Cancer: Innovations, Closing Gaps and Improving Outcomes,” contributing perspectives on the power of radical collaboration and team-science models to accelerate progress......

Continue reading

Canadian scientists join international osteosarcoma team to solve aggressive cancer that targets children and young adults | Globe and Mail

Canadian scientists join international osteosarcoma team to solve aggressive cancer that targets children and young adults November 14, 2025 More than 45 years after Terry Fox ran his Marathon of Hope, a new generation of scientists—backed by a coalition of donors and home-grown Canadian ingenuity—unites to defeat osteosarcoma, the cancer that took Terry's life. Read More at Globe and Mail....

Continue reading

Real-Time Biopsies Reveal Hidden Insights into Glioblastoma Therapy Response | Bioengineer.org

Real-Time Biopsies Reveal Hidden Insights into Glioblastoma Therapy Response October 08, 2025 In a groundbreaking advancement for glioblastoma research, scientists from Break Through Cancer’s Accelerating Glioblastoma Therapies Through Serial Biopsies TeamLab have demonstrated that the oncolytic virus therapy, CAN-3110, sparks a profound and previously undetectable immune response deep within recurrent glioblastoma tumors. Read More at Bioengineer.org...

Continue reading

Experimental Glioblastoma Trial Findings Could Lead to Change in Patient Monitoring and Therapy | GEN

Experimental Glioblastoma Trial Findings Could Lead to Change in Patient Monitoring and Therapy October 08, 2025 Researchers headed by teams at Mass General Brigham Cancer Institute and Harvard Medical School have acquired serial biopsies from two recurrent glioblastoma (rGBM) patients who were involved in an immunotherapy clinical trial, allowing the scientists to safely monitor brain tumor progression and the patients’ responses to treatment. The researchers say their approach captured details that are indiscernible by even the most advanced of imaging methods. Read More at Genetic Engineering and Biotechnology News...

Continue reading

Serial Biopsies Reveal Immune Activation During Treatment for Recurrent Glioblastoma | Gene Online

Serial Biopsies Reveal Immune Activation During Treatment for Recurrent Glioblastoma October 08, 2025 by Mark Chiang A recent multi-institutional study has demonstrated that repeated sampling of brain tumor tissue can reveal immune system activation in response to cancer treatment for patients with recurrent glioblastoma (GBM). The research, conducted by the Accelerating GBM Therapies Through Serial Biopsies TeamLab and led by investigators from the Mass General Brigham Cancer Institute, highlights the potential of serial biopsies to detect treatment responses that may not be visible through traditional imaging techniques. Read More at Gene Online...

Continue reading

Break Through Cancer
101 Rogers Street
Suite 3A
Cambridge, MA 02142
Info@breakthroughcancer.org
1-800-757-9881